Reduce your recruitment timelines

Using our efficient recruitment techniques, adaptive study designs and integrated protocols we can run hybrid studies reducing our sponsors’ drug development time.

Examples of our accelerated recruitment

Accurate costs projection. We conducted a FIH study of Lumasiran in March 2016. Our team helped to accelerate drug development using adaptive study design and provide accurate cost projections through efficient recruitment. Alnylam received marketing authorisation in April 2020.

In a study for Symptomatic Transthyretin Amyloid Cardiomyopathy, Richmond Pharmacology enrolled 11% of patients in a multi-centre study involving 104 global centres.

Reliability and operational scalability. Our in-house recruitment team enrolled 92 hypertensive patients for a global study on behalf of Alnylam, fulfilling 58% of the total cohort. Our patient networks enabled us to rapidly upscale recruitment and reduce the study timelines.

x

We enable rapid drug development

By swiftly adapting strategies to suit the unique demands of individual trials, we ensure resources are invested in the most appropriate recruitment tactics. Frequently recruiting more than our allotted cohort size in multi-centre studies, we enable our sponsors to complete enrolment early.

We are renowned for our recruitment capabilities.

Our dedicated in-house recruitment team delivers a personal service ensuring volunteers are engaged from the first contact to the last appointment.

Get in touch today

Why choose Richmond Pharmacology for Patient Recruitment in Early Phase Studies

TAP OR CLICK A BLOCK BELOW TO LEARN MORE

Strategic and efficient

You will experience a truly personal service.

Read more +

Diverse patient database

Our recruitment database is arguably the largest in Europe.

Read more +

Accurate timeline and cost predictability

We offer invaluable insight into study acceptability and suitability.

Read more +

Volunteer experience

By listening to the feedback of our volunteers, we make continuous improvements to the experience of our research participants.

Read more +

We enrol more patients safely to your study in a shorter time span using our streamlined procedures

Latest news

Characterisation of the Cardiovascular Effects of a Meal: QTcF Assessment and Further Insights into the Physiological Effects

December 4, 2023
Groundbreaking research paper authored by Dr. Georg Ferber, Dr. Dilshat Djumanov, Dr. Ulrike Lorch, Dr. Edward Jackson, Dr. Joao Almeida Melo, Mr. James Rickard, and Dr. Jorg Taubel. 
Read more

Richmond Pharmacology becomes Richmond in Brand Refresh

December 1, 2023
Refreshed brand reflects company’s growth over 22 years and renewed commitment to turning hope into reality for patients.
Read more

Events

The 44th Annual Scientific Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT)

14 – 16 December 2023
We are thrilled to share our participation in the 44th Annual Meeting of the Japan Society of Clinical Pharmacology.
View event